Mahavir Advanced Peer Comparison

BSE: 531689

₹150.65

₹-3.05 (-1.98%)

As on 06-Jan-2015IST

Market cap

₹171 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

660.7

P/B Ratio

19.2

Div. Yield

0 %

Edit

	Mahavir Advanced	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	171	33,904	27,051	26,327	26,160
Revenue (₹ Cr)	0	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	0.26	414.00	288.22	-371.81	387.35
Net Margin (%)	126.96	11.23	14.79	-3.93	26.01
RoE (%)	2.93	8.38	29.77	-3.85	25.18
Price to Earnings	660.72	82.89	93.86	--	67.73
Price-To-Book	19.18	6.73	20.15	3.29	15.16

Income Statement (₹ Cr)

	Mahavir Advanced	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	0.10	4,830.36	41.58	--	76.11
Total Income	0.32	4,914.64	41.73	--	76.68
Total Expenditure	0.18	3,850.53	30.00	--	69.99
EBITDA	-0.08	979.83	11.59	--	6.12
Depreciation	--	139.92	3.35	--	0.80
EBIT	-0.08	839.91	8.24	--	5.32
Interest	0.00	83.35	2.34	--	1.58
Other Income	0.22	84.28	0.14	--	0.56
Exceptional Items	--	49.83	--	--	--
Profit before Tax	0.14	890.67	6.04	--	4.31
Provision for Tax	--	47.88	1.54	--	1.44
Profit after Tax	0.14	842.79	4.50	--	2.86

	Mahavir Advanced	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	8.79	3,581.47	44.83	--	10.77
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	--	1,161.18	10.36	--	1.29
Current Liabilities	0.01	1,743.20	21.34	--	26.33
Total Liabilities	8.80	6,622.02	76.53	--	38.71

	Mahavir Advanced	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	--	3,266.10	51.75	--	7.38
Current Assets	8.80	3,355.92	24.78	--	31.01
Total Assets	8.80	6,622.02	76.53	--	38.71
Total Debt*	0.00	1,906.08	21.09	--	12.17
Net Current Assets	8.79	1,612.72	3.44	--	4.68
Contingent Liabilities	--	267.40	4.70	--	--

	Mahavir Advanced	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	0.49	1,476.29	6.29	--	-0.21
Cash Flow from Investing Activities	--	-851.62	-5.46	--	-2.00
Cash from Financing Activities	8.16	-601.32	-0.58	--	2.17
Net Cash Inflow / Outflow	0.49	23.35	0.25	--	-0.04

	Mahavir Advanced	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	1.58	18.98	13.38	--	29.97
ROE (%)	1.58	30.04	19.08	--	30.26
ROA (%)	1.58	13.36	6.16	--	8.85
EBIT Margin (%)	134.12	22.03	28.21	--	8.78
Net Margin (%)	43.03	17.15	10.78	--	3.74
Cash Profit Margin (%)	133.89	20.32	18.86	--	4.81

	Mahavir Advanced	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-24.66	-13.89	12.11	--	37.10
EBIT Growth (%)	190.36	-49.66	21.82	--	30.95
Net Profit Growth (%)	189.96	-46.64	58.36	--	39.55
EPS Growth (%)	189.96	-56.04	58.36	--	39.55
Book Value Growth (%)	1.59	36.37	21.09	--	32.03

	Mahavir Advanced	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	1,613.77	6.59	0.00	--	0.00
Price / Book Value	25.28	1.55	0.00	--	0.00
Dividend Yield (%)	0.00	2.19	--	--	--
EV/EBITDA	1,607.38	5.73	3.52	--	2.02
Market Cap (₹ Cr)	222.24	5,016.58	0.00	--	0.00

	Mahavir Advanced	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	0.54	0.47	--	1.13
Short term debt to equity ratio	--	0.06	0.23	--	0.84
Current Ratio	976.71	1.93	1.16	--	1.18
Quick Ratio	976.71	1.36	1.11	--	0.75
Interest Coverage	578.18	11.69	3.58	--	3.73

	Mahavir Advanced	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	78.04	9.96	33.85	--	17.81
Asset Turnover	0.01	0.77	0.57	--	2.35
Receivable days	0.00	54.33	106.93	--	58.46
Inventory Days	0.00	77.43	10.49	--	41.85
Payable days	--	120.43	213.33	--	91.25
Cash Conversion Cycle	--	11.32	-95.91	--	9.06

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.